Fecha de publicación: 14/04/2025 Fuente: FierceBiotech Amid an FDA overhaul and market volatility, one biotech executive says her public company still operates with the mentality of a private company, while urging the industry to work together with federal health agencies so drug developers can continue to transform cancer care.